1
|
Feng C, Bao X, Shan L, Ling Y, Ding Y, Wang J, Cao Y, Wang Q, Cui W, Xu S. Calcium-Sensing Receptor Mediates β-Amyloid-Induced Synaptic Formation Impairment and Cognitive Deficits via Regulation of Cytosolic Phospholipase A2/Prostaglandin E2 Metabolic Pathway. Front Aging Neurosci 2020; 12:144. [PMID: 32670047 PMCID: PMC7328130 DOI: 10.3389/fnagi.2020.00144] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Accepted: 04/29/2020] [Indexed: 12/15/2022] Open
Abstract
Calcium-sensing receptor (CaSR) is a G protein-coupled receptor (GPCRs). Soluble β-amyloid peptide (Aβ) is one of the orthosteric modulators of CaSR, while, the role and underlying mechanism of CaSR in cognitive decline in Alzheimer’s disease (AD) is unclear. In this study, molecular technology such as live-cell imaging combined with behavioral tests were used to explore the role and the underlying mechanism of CaSR in the cognitive deficits in AD mice. The expression levels of CaSR were increased both in AD mice and Aβ1–42 (β-amyloid protein)-treated primary cultured neurons. Pharmacological inhibition of CaSR ameliorated recognitive and spatial memory deficits of Aβ1–42-oligomer-treated mice in a dose-dependent manner. Pharmacological inhibition of CaSR or down-regulation of the expression of CaSR by CaSR-shRNA-lentivirus prevented the impairment of filopodia, and the synapse induced by oligomeric Aβ1–42. The contents of cytosolic phospholipase A2 (cPLA2) and prostaglandin E2 (PGE2) in hippocampal neurons and tissue were increased after treatment with Aβ1–42 oligomers. Inhibition or down-regulation of CaSR mediates Aβ-induced synapse formation and cognitive deficits partially, through the activation of the cPLA2/PGE2 pathway. This study provides novel insights on CaSR, which is a promising therapeutic target for AD.
Collapse
Affiliation(s)
- Chenxi Feng
- School of Medicine, Ningbo University, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo, China.,Children's Hospital of Soochow University, Suzhou, China
| | - Xiaoming Bao
- HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, China.,Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China
| | - Ling Shan
- Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, Netherlands
| | - Yunxiang Ling
- School of Medicine, Ningbo University, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo, China
| | - Yanfei Ding
- School of Medicine, Ningbo University, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo, China
| | - Jia Wang
- School of Medicine, Ningbo University, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo, China
| | - Yanzi Cao
- School of Medicine, Ningbo University, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo, China
| | - Qinwen Wang
- School of Medicine, Ningbo University, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo, China
| | - Wei Cui
- School of Medicine, Ningbo University, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo, China
| | - Shujun Xu
- School of Medicine, Ningbo University, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo, China
| |
Collapse
|
2
|
Abstract
This themed issue of the British Journal of Pharmacology stems from the eighth in the series of meetings on the Molecular Pharmacology of G protein coupled receptors (MPGPCR) held as part of a joint meeting with the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) in Melbourne Australia from 7 to 11 December 2014. Linked Articles This article is part of a themed section on Molecular Pharmacology of G Protein-Coupled Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v173.20/issuetoc.
Collapse
Affiliation(s)
- R J Summers
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
| |
Collapse
|